Using Noninvasive Electrophysiology to Determine Time Windows of Neuroprotection in Optic Neuropathies

The goal of neuroprotection in optic neuropathies is to prevent loss of retinal ganglion cells (RGCs) and spare their function. The ideal time window for initiating neuroprotective treatments should be the preclinical period at which RGCs start losing their functional integrity before dying. Noninva...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 23; no. 10; p. 5751
Main Authors Porciatti, Vittorio, Chou, Tsung-Han
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 20.05.2022
MDPI
Subjects
Age
Apoptosis
Biomarkers
Cardiac Electrophysiology
Chronic effects
Clinical trials
Electrophysiology
Electroretinography
Glaucoma
Humans
Hypotheses
Neuroprotection
Optic nerve
Optic Nerve Diseases
optic neuropathy
pattern electroretinogram
Retinal Ganglion Cells
Signal processing
pattern electroretinogram
optic neuropathy
retinal ganglion cells
glaucoma
neuroprotection
Online AccessGet full text

Cover

More Information
Summary:The goal of neuroprotection in optic neuropathies is to prevent loss of retinal ganglion cells (RGCs) and spare their function. The ideal time window for initiating neuroprotective treatments should be the preclinical period at which RGCs start losing their functional integrity before dying. Noninvasive electrophysiological tests such as the Pattern Electroretinogram (PERG) can assess the ability of RGCs to generate electrical signals under a protracted degenerative process in both clinical conditions and experimental models, which may have both diagnostic and prognostic values and provide the rationale for early treatment. The PERG can be used to longitudinally monitor the acute and chronic effects of neuroprotective treatments. User-friendly versions of the PERG technology are now commercially available for both clinical and experimental use.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23105751